Dr. Lim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Health Plaza
East Hanover, NJ 07936Phone+1 862-579-6021
Summary
- Dr. Stephen Lim is a senior medical director for Novartis the CAR-T program. He completed his fellowships in Hematology and Medical Oncology at UCLA David Geffen School of Medicine/UCLA Medical Center and Los Angeles County-Harbor-UCLA Medical Center.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1995
- Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1992 - 1993
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
- David Geffen School of Medicine at UCLAClass of 1989
Certifications & Licensure
- CA State Medical License 1990 - 2026
Publications & Presentations
PubMed
- A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia
Targeted Oncology. 2024-05-01 - 14 citationsKymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.Rakesh Awasthi, Harald J Maier, Jie Zhang, Stephen Lim
Human Vaccines & Immunotherapeutics. 2023-12-31 - 6 citationsRuxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.James R Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao Yang
British Journal of Haematology. 2023-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: